Wilson Patty, Lim Ron
CUPS Medical Clinic, Calgary, AB, Canada (PW); Alberta Health Services Opioid Dependency Program, Calgary, AB, Canada (RL).
J Addict Med. 2022;16(2):246-248. doi: 10.1097/ADM.0000000000000868.
Fentanyl and fentanyl analogs have invaded the street-sourced opioid market in North America which has resulted in an unprecedented number of unintentional opioid overdoses. Existing guidelines to treat opioid use disorder are based on evidence that was developed when heroin was the primary street-sourced opioid and proposed dosages of opioid agonist treatments are increasingly inadequate to address patients with high opioid tolerances.
The authors examine one case study of a patient with an extremely high opioid tolerance and review how responsive dose adjustments outside of the recognized maximum doses allowed for meaningful functional outcomes.
This case demonstrates how patient-centered dose responses with a focus on functional outcomes supersede existing opioids agonist treatment dosing ranges, especially in the context of a patient with a higher than typical opioid tolerance.
芬太尼及其类似物已侵入北美街头来源的阿片类药物市场,导致意外阿片类药物过量服用的数量达到前所未有的程度。现有的治疗阿片类药物使用障碍的指南是基于海洛因是主要街头来源阿片类药物时所产生的证据制定的,而阿片类激动剂治疗的建议剂量越来越不足以应对阿片类药物耐受性高的患者。
作者研究了一名阿片类药物耐受性极高的患者的病例,并回顾了在公认的最大剂量范围之外进行的反应性剂量调整如何实现有意义的功能结果。
该病例表明,以患者为中心、注重功能结果的剂量反应如何超越现有的阿片类激动剂治疗剂量范围,尤其是在阿片类药物耐受性高于典型水平的患者中。